Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. - Wikidata - awgldk - TriplyDB

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

http://www.wikidata.org/entity/Q38075801

about

Profile of certolizumab and its potential in the treatment of psoriatic arthritis Certolizumab pegol (CDP870) for rheumatoid arthritis in adults Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis Intranasal exposure to monoclonal antibody Fab fragments to Japanese cedar pollen Cry j1 suppresses Japanese cedar pollen-induced allergic rhinitis Cytokine networking of innate immunity cells: a potential target of therapy.Active axial spondyloarthritis: potential role of certolizumab pegol.Certolizumab-induced uveitis: a case report and review of the literature.Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.Etanercept: a review of its use in autoimmune inflammatory diseases.Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis

P2860

Q22305856-7E6D7161-B8D3-4235-AEAD-9B84F53289B6 Q24193535-AF8FA0AE-D681-4055-8165-E1302F064DD1 Q35608168-AEB33FF9-7CB8-47E7-9F62-1CAFC05D1939 Q36830128-7D45B247-C09B-4DA4-8C73-E5740650CBD7 Q38180799-81E6F476-E059-4AB9-BF25-EB7C2E6F92AD Q38194547-3E3BDC20-9825-4987-A078-277F5448D958 Q38202641-71FA89D8-B3C5-4630-92B3-DBF1A630303B Q38219589-051D8277-323E-4556-A884-09CBDA705270 Q38230740-251BD661-5010-4E5E-AA50-1EB1DED02565 Q38236706-E8248DD2-0C88-4C9E-8B0E-EBEEE1D5B694 Q39039141-6CA60242-103D-4525-8E16-BA506273D9CB Q57767898-056A31AA-D018-41F6-866A-D0CF8A48A32A Q58699533-5115A241-6484-4163-AD8E-F2516151DD9E Q59221076-3BA69F96-D999-4DF6-9B28-84E589467B84

P2860

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

http://www.wikidata.org/entity/Q38075801

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

@en

type

label

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

@en

prefLabel

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

@en

P1433

Q38075801-9CC5A399-9677-4EEC-8FF8-4CF114EF384D

P1476

Q38075801-9C51F7EE-3DA7-4610-9A65-7F805F574B05

P2093

Q38075801-AD409EAE-4C59-4502-8958-598008DF2447

P2860

Q38075801-0D7333B5-718A-4261-BA85-E8AFE1DFFF9F

Q38075801-25F11BB3-08A1-493E-8147-EC06F0412F13

Q38075801-27674049-571E-4C44-903A-22AB7E18728E

Q38075801-2D7CB578-D0A5-4D7A-ADC9-AE96215D538C

Q38075801-41C70D4C-348C-4739-BBD9-07C31410EBCD

Q38075801-41EABC6E-3B8D-4B63-996B-49331D3B9A29

Q38075801-4741D68F-2CAE-44ED-855C-105F92D2193E

Q38075801-4CCE80E6-4043-432C-B06B-AA5FDB05D766

Q38075801-55D731C7-D8AA-4FC4-B112-E08BA0947787

Q38075801-6EE10078-50FF-4602-A6F3-0B8F2BA1DFE7

P2888

Q38075801-62743A91-F23E-4C09-96FE-8FBD6C4C757E

P304

Q38075801-58FD3CA6-45D4-4FA3-BDD3-A7DD7F03876C

P31

Q38075801-6084E798-CF40-4187-B7B1-7D4F78DB524C

P356

Q38075801-066E9388-F3B9-4469-8386-6C9C223B57A9

P433

Q38075801-5EED5508-14A5-48F8-BB6A-391DE5CBC3FB

P478

Q38075801-DED6E7D7-EACA-4A5B-B1E2-542DAD9F3318

P577

Q38075801-8BFC342A-2201-4EF1-97F1-49E646C4F1FE

P6179

Q38075801-511D4912-6385-4997-9B37-855FDE5565FB

P698

Q38075801-0D841B4D-0867-4AB2-AB9F-D50866D7385C

P356

S40265-013-0009-3

P1433

P1476

Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

@en

P2093

Emma D Deeks

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

The pathogenesis of rheumatoid arthritis

Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol

Rationale of using different biological therapies in rheumatoid arthritis.

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont

Treating rheumatoid arthritis to target: recommendations of an international task force.

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol.

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial

P2888

s40265-013-0009-3

P304

75-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-013-0009-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026046682

http://www.w3.org/2001/XMLSchema#string

P698

23338540

http://www.w3.org/2001/XMLSchema#string